"Naproxen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.
| Descriptor ID |
D009288
|
| MeSH Number(s) |
D02.455.426.559.847.638.472.500 D04.615.638.472.450
|
| Concept/Terms |
Naproxen Sodium- Naproxen Sodium
- Sodium, Naproxen
- Sodium Naproxenate
- Naproxenate, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Naproxen".
Below are MeSH descriptors whose meaning is more specific than "Naproxen".
This graph shows the total number of publications written about "Naproxen" by people in this website by year, and whether "Naproxen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naproxen" by people in Profiles.
-
Heutlinger O, Mathew T, Fujimoto D, Bharani V, Yamarik R, Baz S. Bilirubin Elevation Caused by Naproxen Overdose: A Case Report Highlighting Laboratory Interference. Am J Case Rep. 2023 Oct 16; 24:e941267.
-
Apata J, Pennap DD, Mosholder AD. The use of analgesics for intentional self-poisoning: Trends in U.S. poison center data. J Psychiatr Res. 2023 07; 163:402-405.
-
Kodela R, Nath N, Chattopadhyay M, Nesbitt DE, Vel?zquez-Mart?nez CA, Kashfi K. Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-?B signaling. Drug Des Devel Ther. 2015; 9:4873-82.
-
Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012 Mar 15; 83(6):715-22.
-
Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-?B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010 Dec 08; 298(2):204-11.
-
Eichler HG, Mavros P, Geling O, Hunsche E, Kong S. Association between health-related quality of life and clinical efficacy endpoints in rheumatoid arthritis patients after four weeks treatment with anti-inflammatory agents. Int J Clin Pharmacol Ther. 2005 May; 43(5):209-16.
-
Lovell DJ, Zaoutis TE, Sullivan K. Immunosuppressants, infection, and inflammation. Clin Immunol. 2004 Nov; 113(2):137-9.
-
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004 Jul; 56(7):827-40.
-
Davies NM, R?seth AG, Appleyard CB, McKnight W, Del Soldato P, Calignano A, Cirino G, Wallace JL. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther. 1997 Feb; 11(1):69-79.
-
Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace JL. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol. 1996 Jan; 270(1 Pt 1):G42-8.